ST. PETERSBURG, Fla., May 7, 2012 /PRNewswire/ -- Smith & Nephew (LSE: SN, NYSE: SNN), the global medical technology business, today announces the closing of the acquisition of privately-held Kalypto Medical, Inc., by its group company Smith & Nephew, Inc., adding to Smith & Nephew's own Negative Pressure Wound Therapy (NPWT) innovation pipeline and intellectual property portfolio.
Kalypto Medical is the manufacturer of the NPD 1000, a portable, ambulatory Negative Pressure Wound Therapy (NPWT) system. Kalypto has invested in NPWT innovation since 2006.
"Smith & Nephew entered the NPWT market nearly five years ago with the intent of delivering innovation," commented Robin Carlstein, Senior Vice President at Smith & Nephew's Advanced Wound Management division. "Our RENASYS™ and PICO™ products have disrupted the NPWT market. The acquisition of Kalypto Medical is in alignment with our strategy to bring ever more innovation to this important market, continuing our drive to reduce the human and economic cost of wounds. And through innovations in the NPWT market, we can directly impact the health and economic costs that affect our customers."
Smith & Nephew is not disclosing terms of this transaction.
Note to editors: RENASYS NPWT offers clinicians versatility through a choice of easy to use, intuitive devices and a range of foam and gauze dressing kits – allowing for treatment tailored to the individual needs of each patient. The palm sized PICO system's one-button pump and revolutionary dressing technology that manages fluids without a bulky canister represents an entirely new way to deliver NPWT and brings NPWT to a wider range of patients.
For more information about Smith & Nephew, please visit www.smith-nephew.com.
About Smith & Nephew
Smith & Nephew is a global medical technology business dedicated to helping improve people's lives. With leadership positions in Orthopaedic Reconstruction, Advanced Wound Management, Sports Medicine and Trauma, Smith & Nephew has almost 11,000 employees and a presence in more than 90 countries. Annual sales in 2011 were nearly $4.3 billion. Smith & Nephew is a member of the FTSE100 (LSE: SN, NYSE: SNN).
This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith & Nephew, these factors include: economic and financial conditions in the markets we serve, especially those affecting health care providers, payors and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; strategic actions, including acquisitions and dispositions, our success in integrating acquired businesses, and disruption that may result from changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business or competitive nature. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew's most recent annual report on Form 20-F, for a discussion of certain of these factors.
Any forward-looking statement is based on information available to Smith & Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith & Nephew are qualified by this caution. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith & Nephew's expectations.
™Trademark of Smith & Nephew. Registered US Patent and Trademark Office.